USSN: 10/019,192

Attorney Docket No: 0994.00133

IN THE CLAIMS:

 (Original) A complex for use as a therapeutic pharmaceutical, said complex comprising:

a ligand comprising at least one hydroxyalkyl phosphine donor group bound to a non-radioactive gold atom to form a stable gold-ligand complex.

- 2. (Original) The complex according to claim 1, wherein said gold atom is a gold (I) compound.
- 3. (Original) The complex according to claim 1 wherein said gold-ligand complex further includes a pharmaceutically acceptable carrier.
- 4. (Original) The complex according to claim 1, wherein said gold-ligand complex further includes therapeutic agent.
- 5. (Currently Amended) A method of treating <u>prostate</u>, <u>colon</u>, <u>or gastric</u> cancer comprising the steps of:

administering an effective amount of a complex comprising a ligand comprising at least one hydroxyalkyl phosphine group bound to a non-radioactive gold atom to form a stable gold-ligand complex.

- 6. (Currently Amended) A method of preventing the metastasis of <u>prostate</u>, <u>colon</u>, <u>or gastric</u> cancer comprising the steps of: administering an effective amount of a complex comprising a ligand comprising at least one hydroxyalkyl phosphine group bound to a non- radioactive gold atom to form a stable gold-ligand complex.
- 7. (Currently Amended) A method of arresting cell growth of prostate, colon, or gastric cancer comprising the steps of: administering an effective amount of a

USSN: 10/019,192

Attorney Docket No: 0994.00133

complex comprising a ligand comprising at least one hydroxyalkyl phosphine group bound to a non- radioactive gold atom to form a stable gold-ligand complex.